Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia

PURPOSE: This Phase I dose escalation study was based on the hypothesis that the addition of 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) to cytarabine would enhance cytarabine cytotoxicity. The primary objective of the study was to establish the maximum tolerated dose of 3-AP when give...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Invest New Drugs
Glavni autori: Odenike, Olatoyosi M., Larson, Richard A., Gajria, Devika, Dolan, M. Eileen, Delaney, Shannon M., Karrison, Theodore G., Ratain, Mark J., Stock, Wendy
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283497/
https://ncbi.nlm.nih.gov/pubmed/18217206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-008-9115-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items